Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.6, while State Street SPDR S&P Biotech ETF trades at $154.4. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SGOV | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $100.74 | $164.28 |
52-Week Low | $100.28 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.59, up slightly by 0.01% today. Technical indicators show a bullish trend with strong moving average support, though oscillators are neutral. The ETF provides exposure to short-term U.S. Treasury bills, offering liquidity and a low expense ratio of 0.09%. Recent news highlights institutional interest, such as Advisortrust Partners LLC acquiring a $615,000 position.
The outlook for SGOV is stable, benefiting from its role as a cash management tool amid rate uncertainty. Investment appeal lies in its safety and yield relative to cash, but risks include potential Fed rate hikes impacting short-term bond prices. Investors seeking low-risk income may find SGOV attractive, though returns are modest compared to equities.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
